ExoXpert

🗞️ 𝗡𝗲𝘄 𝗣𝗿𝗲𝘀𝘀-𝗥𝗲𝗹𝗲𝗮𝘀𝗲 𝗘𝗫𝗢 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 & 𝗘𝘅𝗼𝗫𝗽𝗲𝗿𝘁 𝗮𝗰𝗵𝗶𝗲𝘃𝗲 𝘁𝘄𝗼 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆-𝗳𝗶𝗿𝘀𝘁 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗲𝘅𝗼𝘀𝗼𝗺𝗲 𝗳𝗶𝗲𝗹𝗱 - First GMP certification of European exosome-specialist manufacturing facility - Successful loading of mRNA and DNA payloads into GMP-grade exosomes for third-party non-viral drug delivery services "𝙋𝙧𝙚𝙡𝙞𝙢𝙞𝙣𝙖𝙧𝙮 𝙙𝙖𝙩𝙖 𝙛𝙧𝙤𝙢 𝙀𝙭𝙤𝙓𝙥𝙚𝙧𝙩’ 𝙩𝙧𝙞𝙖𝙡𝙨 𝙨𝙝𝙤𝙬 𝙖 𝙧𝙚𝙩𝙚𝙣𝙩𝙞𝙤𝙣 𝙧𝙖𝙩𝙚 𝙪𝙥 𝙩𝙤 80% 𝙤𝙛 𝙩𝙝𝙚 𝙡𝙤𝙖𝙙𝙚𝙙 𝘿𝙉𝘼 𝙘𝙖𝙧𝙜𝙤 𝙪𝙥𝙤𝙣 𝙚𝙭𝙤𝙨𝙤𝙢𝙚 𝙡𝙤𝙖𝙙𝙞𝙣𝙜"

💪 We are proud to be recognized by Labiotech.eu, through our mother company, as one of the 6 companies driving the exosome field.   - EXO Biologics is running the first MSC-EV clinical trial in Europe and is pioneering the regulatory pathway with the GMP ExoPulse manufacturing platform.   - ExoXpert is the leading exosome-specialized CDMO offering the ExoPulse platform for: ➡ Producing GMP grade exosomes as therapeutics ➡ Loading your payload (small molecules, siRNA, RNA, DNA) into GMP grade exosomes as non viral drug delivery system.   Contact us if you want to develop an exosome-based drug product with an experienced manufacturer.

𝐂𝐮𝐫𝐢𝐨𝐮𝐬 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐞𝐱𝐨𝐬𝐨𝐦𝐞-𝐛𝐚𝐬𝐞𝐝 𝐝𝐫𝐮𝐠 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐟𝐨𝐫 𝐑𝐍𝐀 𝐩𝐚𝐲𝐥𝐨𝐚𝐝? Laura Brohée, our R&D leader, will share our latest data 📈 with our clinical-grade exosomes and their drug delivery capacity.   📣 𝗧𝗶𝘁𝗹𝗲: From ongoing Phase I/II trial to RNA delivery preclinical demonstration 📍 𝗪𝗵𝗲𝗿𝗲: Formulation & Delivery Nexus, London, UL 📅 𝗪𝗵𝗲𝗻: 14th November 2024

- How to get to clinic with EV based products ? - Where are we with EV-loading technologies for non viral drug delivery system ? If you are interested in these questions, join the presentation our our CEO Hugues Wallemacq at the Exosome-Based Therapeutic Development Summit in Boston! 🗓️ Date: Wednesday, September 18, 2024 🕒 Time: 9:30 - 10:00 AM 📍 Location: Plenary Session Room, Hilton Airport Hotel 🎙️ Presenter: Hugues Wallemacq, CEO of EXO Biologics and ExoXpert He'll discuss "From ongoing Phase I/II trial to RNAs delivery preclinical demonstration," showcasing how we are pushing the boundaries of exosome-based therapeutics. For more information about the summit, visit: https://lnkd.in/gBdKPAgE While you're there, make sure to connect with Romain du Hecquet de Rauville, our Chief Business Officer to explore partnership opportunities and share insights into the exosome landscape. We can't wait to see you there!

📢 Committed to Quality & Compliance We are thrilled to announce that we’ve officially been inspected by FAMHP for GMP (Good Manufacturing Practices) certification! 🌟   As an exosome-specialized CDMO, this is an essential step in our journey to ensure the highest quality, safety, and compliance standards in everything we do. Our team is fully committed to delivering products that meet global regulatory standards, reinforcing our commitment to supporting exosome product developers.   At ExoXpert, we believe in the potential of exosomes as therapeutics and as vehicles for drug administration. By pursuing GMP certification, we’re making our state-of-the-art production platform even more accessible to clients and partners.   Stay tuned for updates as we work through this significant milestone! Check out how we accelerate EV clinical trials for our partners: https://lnkd.in/evu8K9xQ

We have been invited to provide our thoughts about what the next 10 years could bring to the field of cell and gene therapy manufacturing.   By developing loaded extracellular vesicles , ExoXpert is providing a non-viral drug delivery system to gene therapy companies. Learn more about our vision and achievements with the testimonial of our CBO, Romain du Hecquet de Rauville.   Thanks to Clinical Trials Arena for building this outlook with other inspirational leaders such as David Smith, John W. Hadden II and Alexander Seyf.   https://lnkd.in/exrPgY8v

🙋♀️ You are struggling to produce large quantities of Exosomes/EVs in a consistent way? 🤷♂️ You feel lost about what it takes to get GMP compliant and access clinical trials. 👉 Discover ExoXpert and the ExoPulse platform. Get your exosome/EVs project to clinical stage faster with a platform already used in clinical trials.

📢 Press Release from our mother company: EXO Biologics completes dosing of first cohort in first EMA-approved MSC-based exosome (EXOB-001) clinical trial. The EVENEW study targets Bronchopulmonary Dysplasia, the most common cause of fatality in pre-natal birth. EXOB-001 is also available for our partners for RNA/DNA loading with our ExoPulse platform. You can therefore leverage from our clinical achievements to get a safe & non viral drug delivery system. Our CEO, Hugues Wallemacq, proudly states, "The completion of the first milestone of this trial is a demonstration of EXO Biologics’ ability to translate pioneering, cutting-edge research into the clinical phase through its proprietary technology and expertise.” Link to full Press Release: https://lnkd.in/d7jA_Hte

We are proud to announce that we (EXO Biologics / ExoXpert) have raised up to 16m€ in Serie A funding. The funding will primarily strengthen EXO Biologics’ subsidiary ExoXpert®, the exosome specialist CDMO, support the first EMA approved MSC-derived exosome clinical trial, and fund the ongoing development of the ExoPulse® platform to produce unmodified and RNA or drug-loaded exosomes.

📢 Presse Release : 𝐄𝐱𝐨𝐗𝐩𝐞𝐫𝐭 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐍𝐞𝐮𝐜𝐨𝐫𝐞 𝐁𝐢𝐨 𝐭𝐨 𝐄𝐯𝐚𝐥𝐮𝐚𝐭𝐞 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐄𝐱𝐨𝐬𝐨𝐦𝐞 𝐋𝐨𝐚𝐝𝐢𝐧𝐠 “𝑇ℎ𝑖𝑠 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑠 𝑎𝑛 𝑖𝑚𝑝𝑜𝑟𝑡𝑎𝑛𝑡 𝑠𝑡𝑒𝑝 𝑖𝑛 𝑡ℎ𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑣𝑎𝑙𝑖𝑑𝑎𝑡𝑖𝑜𝑛 𝑎𝑛𝑑 𝑎𝑝𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑜𝑢𝑟 𝐹𝑖𝑋𝐸 𝑝𝑙𝑎𝑡𝑓𝑜𝑟𝑚 𝑢𝑠𝑖𝑛𝑔 𝑎𝑑𝑣𝑎𝑛𝑐𝑒𝑑, 𝑛𝑜𝑛-𝑣𝑖𝑟𝑎𝑙 𝑒𝑥𝑜𝑠𝑜𝑚𝑒𝑠 𝑓𝑜𝑟 𝑡ℎ𝑒𝑟𝑎𝑝𝑒𝑢𝑡𝑖𝑐 𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑦,” “𝑊𝑒 𝑏𝑒𝑙𝑖𝑒𝑣𝑒 𝐸𝑥𝑜𝑋𝑝𝑒𝑟𝑡’𝑠 𝑑𝑒𝑚𝑜𝑛𝑠𝑡𝑟𝑎𝑡𝑒𝑑 𝑒𝑥𝑜𝑠𝑜𝑚𝑒 𝑒𝑥𝑝𝑒𝑟𝑖𝑒𝑛𝑐𝑒 𝑤𝑖𝑡ℎ 𝑖𝑡𝑠 𝐸𝑥𝑜𝑃𝑢𝑙𝑠𝑒 𝑝𝑙𝑎𝑡𝑓𝑜𝑟𝑚 𝑤𝑖𝑙𝑙 𝑒𝑛𝑎𝑏𝑙𝑒 𝑎 ℎ𝑖𝑔ℎ𝑙𝑦 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑎𝑛𝑑 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑣𝑒 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑡𝑜 𝑎𝑛𝑠𝑤𝑒𝑟 𝑡ℎ𝑖𝑠 𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 𝑞𝑢𝑒𝑠𝑡𝑖𝑜𝑛 𝑖𝑛 𝑜𝑢𝑟 𝑠𝑐𝑖𝑒𝑛𝑡𝑖𝑓𝑖𝑐 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦.” 𝐬𝐚𝐢𝐝 𝐊𝐞𝐧𝐧𝐞𝐭𝐡 𝐌𝐨𝐫𝐚𝐧𝐝, 𝐏𝐡𝐃, 𝐂𝐄𝐎, 𝐍𝐞𝐮𝐜𝐨𝐫𝐞 𝐁𝐢𝐨.